​

presentations​

presentations page 2011

21 Dec 2011

Change of Director's Interest Notice

read more >>
19 Dec 2011

Finance News Network Interview with CEO Available on Circadian Website

read more >>
13 Dec 2011

Change of Director's Interest Notice

read more >>
25 Nov 2011

Final Director's Interest Notice

read more >>
24 Nov 2011

Results of Annual General Meeting 24 November 2011

read more >>
24 Nov 2011

Annual General Meeting Presentation 24 November 2011

read more >>
24 Nov 2011

Annual General Meeting Presentation 24 November 2011

read more >>
24 Nov 2011

Chairman's Address to Annual General Meeting 24 November 2011

read more >>
15 Nov 2011

Open Briefing with CEO & MD Robert Klupacs: CEO on IND status for VGX-100

read more >>
31 Oct 2011

Circadian receives FDA IND approval to begin clinical trials with VGX-100 for the treatment of cancer patients with solid tumors

read more >>
25 Oct 2011

Change of Director's Interest Notice

read more >>
24 Oct 2011

Notice of Annual General Meeting and Explanatory Memorandum

read more >>
20 Oct 2011

Change of Director's Interest Notice

read more >>
18 Oct 2011

Final Director's Interest Notice

read more >>
11 Oct 2011

Analyst Investment Research Reports Available on Circadian Website

read more >>
11 Oct 2011

Biopartnering Europe Presentation

read more >>
10 Oct 2011

Healthscope commences clinical validation study of Circadian's Cancer Diagnostic

read more >>
03 Oct 2011

Retirements from Circadian Board of Directors

read more >>
30 Sep 2011

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

read more >>
15 Sep 2011

Open Briefing with CEO & MD Robert Klupacs: FY12 Outlook and VGX-100 Progress

read more >>
13 Sep 2011

VGX-100 identified as potential new therapy for Dry Eye Disease

read more >>
12 Sep 2011

Circadian makes key appointment in clinical trials management

read more >>
11 Sep 2011

VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling

read more >>
09 Sep 2011

Change of Director's Interest Notice

read more >>
07 Sep 2011

Change of Director's Interest Notice

read more >>
07 Sep 2011

Change of Director's Interest Notice

read more >>
07 Sep 2011

Circadian Corporate Presentation - Septemeber 2011

read more >>
06 Sep 2011

Change of Director's Interest Notice

read more >>
31 Aug 2011

Change in Substantial Holding for Optiscan Imaging Limited - Update

read more >>
31 Aug 2011

Change of Director's Interest Notice

read more >>
30 Aug 2011

Change of Director's Interest Notice

read more >>
24 Aug 2011

Preliminary Final Report Appendix 4E Financial Year Ended 30 June 2011

read more >>
25 Jul 2011

Change of Director's Interest Notice

read more >>
18 Jul 2011

Change of Directors Interest Notice

read more >>
14 Jul 2011

Open Briefing with CEO & MD Robert Klupacs

read more >>
16 Jun 2011

Circadian provides market update on clinical development plans for VGX-100 in oncology and eye disease indications

read more >>
16 Jun 2011

Circadian provides market update on clinical development plans for VGX-100 in oncology and eye disease indications

read more >>
14 Jun 2011

Circadian launches Level 1 ADR program and OTCQX Quotation in US

read more >>
10 Jun 2011

Substantial Holding Notice for Antisense Therapeutics Limited

read more >>
07 Jun 2011

VEGF-C and VEGF-D identified as biomarkers for Avastin resistance in colorectal cancer patients

read more >>
07 Jun 2011

VEGF-C and VEGF-D identified as biomarkers for Avastin resistance in colorectal cancer patients

read more >>
30 May 2011

Analyst Investment Research Reports Available on Circadian Website

read more >>
18 Apr 2011

Circadian Technologies (Small Cap Showcase 2011) - Robert Klupacs Presentation

read more >>
07 Apr 2011

Open Briefing with CEO & MD Robert Klupacs on First Phase I Clinical Trial of IMC - 3C5

read more >>
06 Apr 2011

Circadian's VGX-100 Inhibits Tumour Growth in Models of Lung, Ovarian and Prostate Cancer

read more >>
06 Apr 2011

Circadian's partner ImClone Systems commences first Phase 1 clinical trial of VEGFR-3 antibody IMC-3C5

read more >>
02 Apr 2011

The novel therapeutic monoclonal antibody VGX-100 neutralises VEGF-C and inhibits tumor growth and metastasis in subcutaneous and orthotopic models of human cancer

read more >>
22 Mar 2011

New issue announcement, application for quotation of additional securities and agreement

read more >>
15 Feb 2011

31 December 2010 Half-Year Financial Report & Operational Achievements

read more >>
14 Feb 2011

Finance News Network Interview with Circadian CEO Robert Klupacs

read more >>
02 Feb 2011

Circadian Launches First Diagnostic for LAM Lung Disease with U.S. Partner

read more >>
17 Jan 2011

VEGF-D Licence Agreement Open Briefing

read more >>
13 Jan 2011

Chugai Pharmaceutical of Japan Grants Circadian Worldwide Licence to its VEGF-D Intellectual Property Estate

read more >>
11 Jan 2011

2011 Biotech Showcase

read more >>